6505--Notice of Intent to Sole Source Amarillo VAHCS Blood Support Services

Special Notice Notice of Intent to Award a Sole Source Procurement

The Thomas E. Creek VA Health Care System located in Amarillo, Texas has an ongoing need for the supply of blood and blood products from the Oklahoma Blood Institute (OBI). The activity requires a continuous source for various transfusions as well as services related to transfusion screening services on a daily and 24/7 emergency basis.

The names and/or description of the supplies are included at the bottom of this document.

Delivery Address:

Department of Veterans Affairs

Amarillo VAHCS

6010 Amarillo Blvd West

Amarillo, TX 79106-1991

The proposed sole source procurement will be made by an Indefinite Delivery Indefinite Quantity (IDIA) contract with the Oklahoma Blood Institute (OBI).

The requesting activity has submitted a sole source justification request that states that vendor is the only vendor that can provide the necessary products and services to be a direct replacement of the currently provided blood products. Market research has not found an alternate approved vendor that can provide all the required linearity supplies for the services.

This notice is not to be considered a request for quotations or proposals. No contract will be awarded on the basis of offers received in response to this notice; however, all responsible sources may submit a capability statement, proposal or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 5 days from the publication of this notice, a contract will be issued to CAP without any further notice.

The anticipated statutory authority permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements.

DESCRIPTION

ANNUAL ESTIMATES

01A: ABO/Rh (per specimen)

11

02A: Direct Antiglobulin Test (Coombs Test) - single

11

04A: Cold agglutinin low temperature screen

11

04B: Antibody Elution and Red Cell Panel

11

04E: Antibody Absorption and Red Cell Panel

11

04F: Additional Red Cell Antibody Panel

11

11: Washing (per unit) - RBC

1

12: Freezing/Deglycerolization (per unit)

1

12B: Compatibility Testing (per unit) - AHG

20

14: CMV Negative Blood Product (Available Inventory)

1

15A: Fetal Hemoglobin Screen (rosette test)

1

16B: Leukoreduced Red Blood Cells

200

16I: Leukoreduced Red Blood Cells - Irradiated

11

34: Washing (per unit) - Platelet - plus plasma

1

34A: Washing (per unit) - Platelet - plus plasma-A

1

40: AFFP ( 250 + 25ml) x 2 Apheresis Derived

1

40-2: AFFP ( 250 + 25ml) x 1 Apheresis Derived

11

40CCP: COVID-19 Convalescent Plasma, (CCP) ~200 ml dose, High Titer

1

40PED: AFFP (100 + 10ml) x 1 Apheresis Derived

1

42: FFP-WBD 1 x 250ml (250 + 25 ml) Whole Blood Derived

1

42HR: FP-24 (Frozen < 24 hours) 1 x 250ml (250 + 25ml)

11

42PED: FP-24 (Frozen < 24 hours) 1 x 100ml (100 + 10 ml)

1

44: Cryoprecipitated AHF

1

44PD: Cryoprecipitate Pool of 5 (includes pooling fee)

11

44PD10: Cryoprecipitate Pool of 10 (includes pooling fee)

1

50: Plasma AHF Removed

1

61: Leukoreduced Apheresis Platelets

20

61I: Leukoreduced Apheresis Platelets - Irradiated

11

96: Autologous Collection (per component)

1

97: Directed Collection (per component)

1

99C: Aliquot Bags, Pediatric (attached, per set)

1

DI3: Wra Antigen Type

1

EXT: Extraction of DNA for red cell phenotype by molecular method

10

FC10: Pooled Fibrinogen Complex 1.0, Psoralen Treated - 740 mg Fibrinogen (mean)

1

FC15: Pooled Fibrinogen Complex 1.5, Psoralen Treated - 1,457 mg Fibrinogen (mean

1

FC20: Pooled Fibrinogen Complex 2.0, Psoralen Treated - 2,220 mg Fibrinogen (mean)

1

FC30: Pooled Fibrinogen Complex 3.0, Psoralen Treated - 3,117 mg Fibrinogen (mean)

1

FC40: Pooled Fibrinogen Complex 4.0, Psoralen Treated - 3,700 mg Fibrinogen (mean)

1

FY1: Fya Antigen Type

11

FY2: Fyb Antigen Type

1

JK1: Jka Antigen Type

11

JK2: Jkb Antigen Type

1

K1: K Antigen Type

11

K2: k Antigen Type

1

K3: Kpa Antigen Type

1

L03: Antibody Screen

11

L04: Antibody Identification (includes ABO/Rh, antibody screen, comprehensive DAT, red cell panel, written consultation report, medical consultation as needed.)

11

L07: Antibody Titer

1

L08: After hours Tech call Fee: Surcharge per patient request

11

DESCRIPTION

ANNUAL ESTIMATES

L12: Compatibility Testing (per unit) - Immediate Spin

1

L13: Pretreatment of Serum (eg. DTT, Rest, Plasma Neutralization, Urine Inhibition, Lewis Neutralization, P1 Neutralization)

1

L14: Pretreatment of RBCs (eg. DTT, CDP, EGA, Ficin, Density Gradient Separation, Neocytes)

11

L15: Fetal Hemoglobin Stain (Kliehauer Betke)

1

L30: Blood Component Preparation for each order to cover the preparation of the blood component for transport and transfusion.

Â

11

L31: Sample resubmission

1

L32: Cancellation Fee charged when an order is cancelled once a driver is dispatched.

1

L35: Shipping Fee - Specimen Transport or Reagents Shipped Without Blood

1

L89: Sickle Cell Testing (per unit)

1

LE1: Lea Antigen Type

1

LE2: Leb Antigen Type

1

LVDS: Platelet Large Volume Delayed Sampling Fee

11

MS1: M Antigen Type

11

MS2: N Antigen Type

11

MS3: S Antigen Type

1

End of Document